MX2012002427A - Anticuerpos anticina que se unen a quimiocinas cc multiples. - Google Patents

Anticuerpos anticina que se unen a quimiocinas cc multiples.

Info

Publication number
MX2012002427A
MX2012002427A MX2012002427A MX2012002427A MX2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A
Authority
MX
Mexico
Prior art keywords
chemokines
antikine
bind
antikine antibodies
antibodies
Prior art date
Application number
MX2012002427A
Other languages
English (en)
Spanish (es)
Inventor
Dan Allison
Carol Raport
Original Assignee
Vlst Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlst Corp filed Critical Vlst Corp
Publication of MX2012002427A publication Critical patent/MX2012002427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2012002427A 2009-08-28 2010-08-27 Anticuerpos anticina que se unen a quimiocinas cc multiples. MX2012002427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23801509P 2009-08-28 2009-08-28
PCT/US2010/047004 WO2011025962A1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines

Publications (1)

Publication Number Publication Date
MX2012002427A true MX2012002427A (es) 2012-08-03

Family

ID=43628404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002427A MX2012002427A (es) 2009-08-28 2010-08-27 Anticuerpos anticina que se unen a quimiocinas cc multiples.

Country Status (18)

Country Link
US (3) US8313747B2 (cg-RX-API-DMAC7.html)
EP (1) EP2470671B1 (cg-RX-API-DMAC7.html)
JP (2) JP6109571B2 (cg-RX-API-DMAC7.html)
KR (1) KR101778813B1 (cg-RX-API-DMAC7.html)
CN (1) CN102782148B (cg-RX-API-DMAC7.html)
AU (1) AU2010286516B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004387A2 (cg-RX-API-DMAC7.html)
CA (1) CA2771781C (cg-RX-API-DMAC7.html)
DK (1) DK2470671T3 (cg-RX-API-DMAC7.html)
ES (1) ES2531561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150162T1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01769A (cg-RX-API-DMAC7.html)
MX (1) MX2012002427A (cg-RX-API-DMAC7.html)
PL (1) PL2470671T3 (cg-RX-API-DMAC7.html)
PT (1) PT2470671E (cg-RX-API-DMAC7.html)
SI (1) SI2470671T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500011B (cg-RX-API-DMAC7.html)
WO (1) WO2011025962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002427A (es) * 2009-08-28 2012-08-03 Vlst Corp Anticuerpos anticina que se unen a quimiocinas cc multiples.
WO2012172341A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cancer
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
EP2763540A4 (en) * 2011-09-09 2015-04-22 Univ Yale COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES
DK3489261T3 (da) 2012-08-24 2020-12-14 Univ California Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
JO3580B1 (ar) * 2013-03-15 2020-07-05 Lilly Co Eli أجسام مضادة لكيموكين elr+ cxc شامل
AU2014268316B2 (en) * 2013-05-23 2019-10-10 Takeda Pharmaceutical Company Limited Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
JP6220222B2 (ja) * 2013-10-28 2017-10-25 シスメックス株式会社 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品
ES2758508T3 (es) * 2013-12-09 2020-05-05 Allakos Inc Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos
AU2015222757B2 (en) 2014-02-28 2020-10-08 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
EP3114139B1 (en) * 2014-03-04 2022-06-15 Chemomab Ltd. Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
TWI576112B (zh) * 2014-10-24 2017-04-01 國立陽明大學 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用以保護胰臟及防止血糖升高的用途
HUE067123T2 (hu) 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
CA2987797A1 (en) 2015-06-17 2016-12-22 Christopher Robert Bebbington Methods and compositions for treating fibrotic diseases
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
JP7109007B2 (ja) 2016-06-27 2022-07-29 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア がん治療の組み合わせ
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11733232B2 (en) 2017-03-01 2023-08-22 National University Corporation Hokkaido University Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same
RU2740438C1 (ru) * 2017-04-05 2021-01-14 Корея Рисерч Инститьют Оф Байосайенс Энд Байотекнолоджи Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их
CN110831628A (zh) 2017-05-05 2020-02-21 爱乐科斯公司 用于治疗过敏性眼病的方法和组合物
WO2019037067A1 (zh) * 2017-08-25 2019-02-28 法玛科技顾问股份有限公司 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途
EP3694887A4 (en) * 2017-10-13 2022-02-23 A & G Pharmaceutical, Inc. MONOCLONAL ANTIBODIES AND CONJUGATES TO PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
WO2019165397A1 (en) * 2018-02-26 2019-08-29 Cornell University Quantitative biomarkers of ehv-1 susceptibility and protection
CA3099974A1 (en) 2018-05-11 2019-11-14 Halcyon Therapeutics, Inc. Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN110117329B (zh) * 2019-04-03 2020-12-08 河北浓孚雨生物科技有限公司 包含趋化因子与结合伴侣的融合多肽及其用途
KR102489282B1 (ko) * 2019-07-02 2023-01-17 고려대학교 산학협력단 Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물
CA3145667A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN113893331B (zh) * 2020-07-06 2024-11-26 中国农业科学院特产研究所 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用
EP4178614A4 (en) * 2020-07-08 2024-10-30 Georgia Tech Research Corporation COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SARS-COV-2 VIRUS INFECTIONS
IL302078A (en) * 2020-10-16 2023-06-01 Lanova Medicines Ltd Anti-ccr8 monoclonal antibodies and uses thereof
CN115598111B (zh) * 2021-07-08 2025-03-25 南京大学 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法
CN114990073A (zh) * 2022-05-27 2022-09-02 河南农业大学 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6316420B1 (en) 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
UA87979C2 (ru) 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
AU2003293096B9 (en) 2002-11-27 2011-09-29 Biogen Ma Inc. Humanized antibodies against monocyte chemotactic proteins
EP1828234B1 (en) 2004-12-21 2009-03-25 Laboratoires Serono S.A. Cc-chemokine antagonists
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
MX2012002427A (es) * 2009-08-28 2012-08-03 Vlst Corp Anticuerpos anticina que se unen a quimiocinas cc multiples.

Also Published As

Publication number Publication date
EP2470671B1 (en) 2014-12-24
AU2010286516A2 (en) 2012-06-14
US20150166647A1 (en) 2015-06-18
SMT201500011B (it) 2015-03-05
BR112012004387A2 (pt) 2015-09-08
WO2011025962A1 (en) 2011-03-03
IN2012DN01769A (cg-RX-API-DMAC7.html) 2015-06-05
JP2013503192A (ja) 2013-01-31
JP2016135783A (ja) 2016-07-28
PT2470671E (pt) 2015-02-05
ES2531561T3 (es) 2015-03-17
AU2010286516A1 (en) 2012-03-08
CN102782148A (zh) 2012-11-14
HRP20150162T1 (hr) 2015-05-08
US9005617B2 (en) 2015-04-14
AU2010286516B2 (en) 2016-10-06
US20130108640A1 (en) 2013-05-02
EP2470671A4 (en) 2013-04-03
KR101778813B1 (ko) 2017-09-14
EP2470671A1 (en) 2012-07-04
CA2771781C (en) 2019-01-15
US20110059107A1 (en) 2011-03-10
US8313747B2 (en) 2012-11-20
PL2470671T3 (pl) 2015-05-29
CA2771781A1 (en) 2011-03-03
SI2470671T1 (sl) 2015-04-30
JP6109571B2 (ja) 2017-04-05
RU2012111820A (ru) 2013-10-10
KR20120091013A (ko) 2012-08-17
DK2470671T3 (en) 2015-02-09
CN102782148B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
MX2012002427A (es) Anticuerpos anticina que se unen a quimiocinas cc multiples.
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
MX2013003182A (es) Purificacion de anticuerpos por cromatografia de lecho movil simulada.
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
NZ602176A (en) Cd37-binding molecules and immunoconjugates thereof
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
MX2019001355A (es) Anticuerpos monoclonales multiespecíficos.
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
TN2013000292A1 (en) Antibody molecules which bind il-17a and il-17f
MX2012000841A (es) Optimizacion de la produccion de anticuerpos.
MX2014014065A (es) Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
WO2013177101A3 (en) Il-17a/f il-23 bispecific antibodies and their uses
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
WO2013186630A3 (en) Humanized antibodies to ca215
CY1116009T1 (el) Αντισωματα αντικινες που προσδενονται σε πολλαπλες χημειοκινες cc
MX2020010187A (es) Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
AU2016219622A1 (en) Heterodimeric antibody FC-containing proteins and methods for production thereof
NZ779866A (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: REGENERON PHARMACEUTICALS, INC.

FG Grant or registration